Gastrointestinal Cancer

Useful Online Resources and Clinical Trials for Gastrointestinal Cancers

ColoPrint, a microarray-based gene signature test, accurately identifi ed the risk of recurrence of colorectal cancer in patients with localized stage II disease, raising the potential of an exciting new prognostic tool for clinicians.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

In the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) phase III study involving patients with pancreatic neuroendocrine tumors (NET)

A black Labrador retriever was able to detect colorectal cancer >90% of the time when sniffing a patient%u2019s breath or stool sample.

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

The risk of colorectal cancer declined by 33% among postmenopausal women taking oral bisphosphonates for osteoporosis

In situ hybridization (ISH) yields the best results for assessing HER2 expression in gastric cancer, according to a multilaboratory analysis of testing methods.

An analysis of the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database showed that advanced gastric or esophageal cancer confers a poor prognosis

Patients with gastrointestinal stromal tumors (GIST) had stable plasma concentrations of imatinib during long-term treatment, reported Yoon-Koo Kang, MD, PhD, and colleagues at the Gastrointestinal Cancers Symposium.

The results of a large, multicenter trial showed that the addition of bevacizumab to adjuvant chemotherapy failed to improve disease-free survival (DFS) compared with chemotherapy alone.

At the 2011 symposium in San Francisco, California, Oncology & Biotech News spoke with the author of one of the featured presentations at the meeting

Few cancers have a bleaker outlook than pancreatic cancer.

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.

New pancreatic cancer vaccine findings were presented at the 2007 Gastrointestinal Cancers Symposium, held January 19-21 in Orlando, FL.

An oral therapy currently utilized in the treatment of advanced kidney cancer may be on the threshold of obtaining a major new indication.

The European Commission has granted marketing authorization to sorafenib (Nexavar) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.

In an oral presentation, Ann-Lii Cheng, MD, PhD, National Taiwan University Hospital, Taipei, Taiwan, highlighted the results of a phase III study evaluating the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced hepatocellular carcinoma (HCC).

Although gemcitabine-based chemotherapy is standard in advanced pancreatic cancer, the role of adjuvant chemotherapy is still incompletely defined.

A new study shows that less than one half of older patients successfully treated for colorectal cancer receive the recommended screening schedule to detect any recurrence of cancer. The analysis indicates poor compliance with recommended monitoring of colorectal cancer survivors could affect survival.

The 10th Annual Meeting of the World Congress on Gastrointestinal Cancer was held in Barcelona, Spain, in June. The Congress has grown into a key scientific program that covers malignancies affecting every component of the gastrointestinal tract and all facets of patient care, including screening, diagnosis, and management options for common and uncommon tumors.

This month's issue features highlights from the 10th World Congress on Gastrointestinal Cancer (WCGC), held this past June in Barcelona, Spain. The WCGC is an annual meeting that provides scientific sessions and posters on various malignancies of the gastrointestinal tract.

Scientists at the Dana-Farber Cancer Institute, Boston, Massachusetts, have linked the CDK8 gene to colon cancer, a previously unsuspected association.